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Abstract
Introduction The receptor for advanced glycation end products
(RAGE) is a member of the immunoglobulin superfamily of cell
surface receptor molecules. High concentrations of three of its
putative proinflammatory ligands, S100A8/A9 complex
(calprotectin), S100A8, and S100A12, are found in rheumatoid
arthritis (RA) serum and synovial fluid. In contrast, soluble RAGE
(sRAGE) may prevent proinflammatory effects by acting as a
decoy. This study evaluated the serum levels of S100A9,
S100A8, S100A12 and sRAGE in RA patients, to determine
their relationship to inflammation and joint and vascular damage.
Methods Serum sRAGE, S100A9, S100A8 and S100A12
levels from 138 patients with established RA and 44 healthy
controls were measured by ELISA and compared by unpaired t
test. In RA patients, associations with disease activity and
severity variables were analyzed by simple and multiple linear
regressions.
Results Serum S100A9, S100A8 and S100A12 levels were
correlated in RA patients. S100A9 levels were associated with
body mass index (BMI), and with serum levels of S100A8 and
S100A12. S100A8 levels were associated with serum levels of
S100A9, presence of anti-citrullinated peptide antibodies
(ACPA), and rheumatoid factor (RF). S100A12 levels were
associated with presence of ACPA, history of diabetes, and
serum S100A9 levels. sRAGE levels were negatively associated
with serum levels of C-reactive protein (CRP) and high-density
lipoprotein (HDL), history of vasculitis, and the presence of the
RAGE 82Ser polymorphism.
Conclusions sRAGE and S100 proteins were associated not
just with RA inflammation and autoantibody production, but also
with classical vascular risk factors for end-organ damage.
Consistent with its role as a RAGE decoy molecule, sRAGE had
the opposite effects to S100 proteins in that S100 proteins
were associated with autoantibodies and vascular risk, whereas
sRAGE was associated with protection against joint and
vascular damage. These data suggest that RAGE activity
influences co-development of joint and vascular disease in
rheumatoid arthritis patients.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease
that leads to bone and cartilage destruction and extra-articular
complications, including atherosclerotic vascular disease and
premature mortality [1]. The receptor for advanced glycation
end products (RAGE) has been implicated in the pathogene-
sis of RA through its ability to amplify inflammatory pathways
[2,3]. A member of the immunoglobulin superfamily of cell sur-
face receptors, RAGE binds advanced glycation end products
(AGEs), which are non-enzymatically glycated or oxidized
ACPA: anti-citrullinated peptide antibodies; ACR: American College of Rheumatology; AGE: advanced glycation end product; BMI: body-mass index; 
CrCl: creatinine clearance; CRP: C-reactive protein; CT: computed tomography; CV: cardiovascular; ECG: electrocardiogram; ESR: erythrocyte sed-
imentation rate; HDL: high-density lipoprotein; HMGB1: high mobility group box chromosomal protein; HR: hazard ratio; LDL: low density lipoprotein; 
MI: myocardial infarction; PCR: polymerase chain reaction; RA: rheumatoid arthritis; RAGE: receptor for advanced glycation end products; RF: rheu-
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proteins, lipids and nucleic acids formed under conditions of
oxidative stress and hyperglycemia (reviewed in [4]). In addi-
tion to these, RAGE binds some proinflammatory ligands,
including members of the S100/calgranulin family, and high
mobility group box chromosomal protein 1 (HMGB-1), which
is implicated in cell signaling by synergizing with DNA CpG
motifs [5,6]. Several RAGE ligands are characteristically over-
expressed in RA and psoriatic arthritis, compared to healthy
controls [7-9]. S100A8/A9 (calprotectin) and S100A12 (cal-
granulin C, EN-RAGE) levels are significantly elevated in
serum and synovial fluid from RA patients compared to healthy
normal donors [3,10]. S100A8/A9 levels are also higher in
supernatants of cultured RA synoviocytes than of osteoarthri-
tis synoviocytes [11].
Soluble C-truncated RAGE (sRAGE) lacks the transmem-
brane and cytosolic domains of the full-length receptor and
can prevent proinflammatory effects of RAGE signaling by act-
ing as a decoy [12-14]. For example, in a collagen-induced
arthritis (CIA) murine model, treatment with murine sRAGE
significantly reduced joint inflammation and destruction [15].
Serum or plasma levels of sRAGE from patients with RA,
hypertension or metabolic syndrome were lower than those in
healthy subjects [16-18], suggesting that sRAGE levels may
identify those RA patients exposed to high levels of RAGE lig-
ands. A gain-of-function Gly82Ser polymorphism in the RAGE
gene (RAGE 82Ser) occurs more frequently in RA patients
than in healthy controls [19]. Monocytes expressing the RAGE
82Ser allele activated a stronger inflammatory response to
S100A12 in vitro [15]. Although this might be predicted to
contribute to enhanced proinflammatory mechanisms in RA,
we found no evidence that patients with the RAGE 82S allele
had higher levels of inflammation, or a greater likelihood of
complicating cardiovascular (CV) events [19].
Most S100 proteins have a mass between 9 and 14 kDa, and
are characterized by two calcium binding sites of the EF-hand
type (helix-loop-helix) [20]. S100A8 and S100A9, generally
functioning as the S100A8/A9 heterocomplex, and S100A12
are implicated in non-infectious chronic inflammatory diseases
such as RA, psoriasis and inflammatory bowel disease [21-
25]. Longitudinal and cross-sectional studies suggest a rela-
tionship between S100A12 and RA disease activity [26-28].
The S100A12 gene is rapidly upregulated in human monocy-
toid cells and blood monocytes by tumor necrosis factor (TNF)
and lipopolysaccharide (LPS), suggesting its production in
response to proinflammatory signals in RA [10,25]. S100A12
is a potent monocyte chemoattractant and activates mast
cells, which are important effector cells in RA and atheroscle-
rosis [25,29,30]. S100A12 is also proposed to promote proin-
flammatory activities by binding and activating RAGE [31].
However, these studies were established using a murine
model, and since it was later shown that mice have no
S100A12 in their genome [20], alternate receptors are impli-
cated [25]. In addition, recombinant S100 ligands may contain
contaminating endotoxin, and their effects may not always be
fully RAGE dependent [32].
S100A8 and S100A9 regulate leukocyte migration and adhe-
sion [33]. The S100A8/A9 complex has antimicrobial effects,
transports arachidonic acid to endothelial cells, and activates
expression of endothelial cell adhesion molecules [11,34,35].
Although the receptor for S100A8/A9 complex is still
unknown, RAGE has been implicated in some circumstances
[36]. Murine S100A8 stimulates proatherogenic activity, such
as uptake of low-density lipoprotein (LDL), in macrophages.
S100A8 is a key target of oxidation by peroxide, hypochlorite
and nitric oxide [37,38]. Furthermore, S100A9 and S100A12
are implicated in vascular damage, whereas sRAGE is associ-
ated with vascular protection in atherosclerosis [30,39-41].
The relationship between S100 protein levels and vascular
disease or risk factors in RA patients has not been examined
to date. We measured serum levels of S100A8, S100A9 het-
erocomplexes, S100A12 and sRAGE in a previously charac-
terized cohort of established RA patients to identify their
possible relationship to joint and vascular damage and risk fac-
tors in RA patients [19]. We report associations of each pro-
tein with both joint and vascular disease and their risk factors.
Materials and methods
Subjects
The cohort of RA patients met the American College of Rheu-
matology (ACR) 1987 revised criteria for the classification of
RA, and has been previously described [42]. These patients
presented for a scheduled appointment over a 5-month period
(July to November 2003) at our tertiary hospital rheumatology
clinic, as described previously [19]. Patients completed a
questionnaire detailing CV history, risk factors, treatment, and
details of RA. Each patient was clinically evaluated, with chart
review to confirm history, at least once. The study protocol was
approved by the Princess Alexandra Hospital Research Ethics
Committee. Healthy controls (n = 44) without RA or CV dis-
ease were recruited by advertisement. All patients and con-
trols signed informed consent to participate. No prospective
follow-up was carried out in this study.
Measurement of S100 proteins
The serum levels of S100A8, S100A9 and S100A12 levels
were measured using in-house affinity-purified rabbit polyclo-
nal sandwich ELISAs exactly as described for S100A12 [25].
Antibodies to S100A8 did not cross-react with S100A9 (and
did not recognize S100A8/A9 complexes) or S100A12, anti-
S100A9 detected free S100A9 and S100A9 as an S100A8/
A9 complex; anti-S100A12 was immunoadsorbed with
S100A8 and S100A9 [25] and did not cross-react with these
when tested by ELISA or immunoblotting. Standard curves
were constructed with the relevant recombinant S100
proteins.Available online http://arthritis-research.com/content/11/2/R39
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Measurement of sRAGE
sRAGE levels in sera were determined by RAGE Immu-
noassay (R&D Systems, Minneapolis, MN, USA) in an ELISA
format, with wells coated with murine anti-human RAGE mAb
in which serum samples (50 l/well, normally 1:2 v/v dilution)
were incubated. A polyclonal capture antibody against the
extracellular domain of RAGE was used for detection. The min-
imum detectable sRAGE concentration is 4.12 pg/ml accord-
ing to the manufacturer, and the interassay coefficient of
variation is < 8% [41].
Ascertainment of CV events and risk factors, and 
features of RA
To ascertain CV events, patients were asked for a history,
dates and treatments of myocardial infarction, angina, stroke,
transient ischemic attack or peripheral vascular disease, and
these events were verified by medical record review. Although
a number of patients had events prior to the diagnosis of RA,
only those CV events that occurred after RA diagnosis were
included in the current analysis. Patients with multiple events
had only one event counted per person. Myocardial infarction
was identified if subjects developed either of; (1) typical rise
and fall of biochemical markers (troponin or creatine kinase-
MB (CK-MB)) consistent with myocardial necrosis with at
least one of the following (a) ischemic symptoms, (b) develop-
ment of pathological Q waves on the electrocardiogram
(ECG), (c) ECG changes indicative of ischemia (ST segment
elevation or depression); (2) either new pathological Q waves
on serial ECGs or pathological changes of healed or healing
infarction [43]. Stroke or transient ischemic attack were iden-
tified if subjects had been admitted to the hospital with CT evi-
dence of ischemic occlusion or with carotid endarterectomy,
or the subject presented with stroke/transient ischemic attack
(TIA) symptoms with significant plaque on the carotid ultra-
sound and neurological sequelae, with exclusion of subarach-
noid hemorrhage and space occupying lesions. Peripheral
vascular disease was confirmed if Doppler ultrasonography
showed significant large vessel disease.
Cigarette smoking was assessed by questionnaire, which
included details about past and present smoking habits,
number of cigarettes smoked per day and smoking duration.
History of diabetes mellitus was identified if subjects had been
diagnosed by a physician, were taking anti-diabetic medica-
tions, or had an elevated fasting glucose at the time of the
assessment. Family history of CV disease or cerebrovascular
attack before age of 65 in first-degree relatives was deter-
mined by questionnaire. History was not included if a stroke
was deemed hemorrhagic. Body mass index (BMI) was calcu-
lated as weight in kilograms divided by the square of the height
in meters. Blood pressure was measured at the time of evalu-
ation. History of hypercholesterolemia and hypertension were
identified if the diagnoses were recorded in medical records
by a physician, if patients were taking lipid-lowering or antihy-
pertensive drugs, or if elevated blood pressure or fasting cho-
lesterol levels were found at the time of the evaluation. The
percentage risk of coronary heart disease over the next 10
years was estimated using the 'CVD Risk Calculator' based on
the Framingham Study [44] for patients between 30 and 74
years of age and without a history of coronary heart disease.
Metabolic syndrome (modified American Heart Association
(AHA) standard [45]) was identified by the presence of three
or more of these components: (1) BMI > 30; (2) fasting blood
triglycerides  150 mg/dl; (3) blood high-density lipoprotein
(HDL) cholesterol (men: < 40 mg/dl (1.03 mmol/l), women: <
50 mg/dl (1.3mmol/l)); (4) blood pressure  130/85 mmHg;
and (5) fasting glucose  100 mg/dl.
Laboratory data collected at the time of clinical evaluation
included fasting total cholesterol, LDL, HDL, very low-density
lipoprotein (VLDL), triglycerides, LDL/HDL cholesterol ratio,
glucose, creatinine, C-reactive protein (CRP), erythrocyte sed-
imentation rate (ESR), anti-citrullinated peptide antibodies
(ACPA) and rheumatoid factor (RF). A 12-lead ECG carried
out within the previous 12 months was scored for evidence of
Q waves to ascertain possible silent coronary disease. Creat-
inine clearance (CrCl) was estimated for each patient on the
basis of serum creatinine (SCr), age (years), and ideal body
weight (kg) using the Cockcroft and Gault method as follows:
CrCl (ml/min) = [(140 - age)(ideal wt)]/833 × SCr (mmol/l) ×
0.85 for females [46]. Hand radiographs carried out at the
time of evaluation were scored for erosions and joint space
narrowing using the modified Sharp score [47].
Genotyping
High resolution human leukocyte antigen (HLA)-DRB1 geno-
typing was carried out on buffy coat DNA using PCR and
sequence-specific oligonucleotide probes. PCR-based
restriction fragment length polymorphism (RFLP) analysis was
used to delineate the RAGE Gly82Ser and protein tyrosine
phosphatase, non-receptor type 22 (PTPN22) Cys1858Thr
polymorphisms as described [15,48]. Shared epitope was
considered positive when at least one DRB1 allele was one of
the RA susceptibility alleles, as previously described [49].
Statistical analysis
Data were analyzed using STATA 9.1 (StataCorp, College
Station, TX, USA). The variables included age, sex, BMI, cur-
rent and previous smoking status, RF, ACPA, history of CV
events, fasting glucose, homocysteine, cholesterol and triglyc-
eride, ESR, CRP, HDL, LDL, creatinine, CrCl, systolic and
diastolic blood pressure, history of diabetes or elevated blood
sugar level, history of hyperlipidemia or elevated cholesterol,
HLA-DRB1 genotype, Sharp erosion score, Sharp joint space
narrowing score, RAGE Gly82Ser polymorphism, history of
hypertension or elevated blood pressure, metabolic syndrome
(modified AHA standard), serum S100A9, S100A8,
S100A12 and sRAGE. Before further analysis, each variable
was examined for normal distribution by histogram and box
plot. If a variable was not normally distributed, it wasArthritis Research & Therapy    Vol 11 No 2    Chen et al.
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transformed (either logarithmic base e or square root transfor-
mation) before further analysis. Results are reported as mean
± standard deviation (SD).
Unpaired t tests compared the serum levels of S100A9,
S100A8, S100A12 and sRAGE between RA patients and
healthy controls. Simple linear regression analysis was used to
evaluate the relationship between a variable and the serum
concentration of sRAGE or S100 proteins. Variables with P <
0.1 using this method were then subjected to multiple linear
regression (MLR) analysis. An interaction and residual analysis
was also performed on the MLR data. P values < 0.05 (two-
tailed) were considered statistically significant.
Results
Clinical features of the RA cohort
We studied 138 patients with RA (mean age 64.0 years, range
17 to 87 years) and 44 healthy controls (mean age 62 years,
range 44 to 80 years) with neither RA nor CV disease. The RA
patients were characterized for RA clinical variables, CV risk
factors, and RA complications such as vasculitis, radiographic
changes, and CV events (Table 1).
Increased serum concentrations of the S100 proteins, 
but not sRAGE, in patients with established RA
Serum levels of S100A9, S100A8 and S100A12 in patients
with RA (n = 138) were increased relative to serum levels in
healthy controls (n = 44, P < 0.001). The S100A9 levels
detected in patient sera with an anti-S100A9 antibody that
detected S100A9, and S100A9 complexed with S100A8,
were some 100-fold lower than those reported in other studies
[26,27]. This could reflect differences in the specificity of the
anti-calprotectin (an antibody generated against the S100A8/
A9 complex) used by others; the anti-S100A9 used by us was
generated against pure S100A9. In contrast to the S100 pro-
teins, serum levels of sRAGE were not different (Figure 1a–d).
Table 1
Demographic details, cardiovascular risk factors, features of 
rheumatoid arthritis (RA) and its control in the study 
population (n = 138)
Parameter Value
Demographics:
Age (years) 64.0 (10.9)
Females, n (%) 92 (66.7)
Duration of RA (years) 17.6 (13.6)
RF positive, n (%) 83 (61.0)
CV disease:
History of MI, n (%) 14 (10.1)
History of angina, n (%) 11 (8.0)
History of stroke/TIA, n (%) 9 (6.5)
History of PVD, n (%) 6 (4.4)
Any vascular event, n (%) 26 (18.8)
Risk factors for CV diseases:
Smoking pack-year history 18 (24)
Current smoker, n (%) 25 (18.1)
History of hypertension, n (%) 47 (34.1)
History of hyperlipidemia, n (%) 33 (23.9)
History of diabetes, n (%) 19 (13.8)
Family history CV disease, n (%) 38 (27.5)
Clinical findings:
BMI (kg/m2) 27.5 (6.9)
Systolic BP (mmHg) 132 (19)
Diastolic BP (mmHg) 78 (10)
Laboratory tests:
ESR (mm/h) 25 (18)
CRP (mg/l) 13.6 (18.6)
Total cholesterol (mmol/l) 5.3 (1.0)
HDL cholesterol (mmol/l) 1.5 (0.4)
LDL cholesterol (mmol/l) 3.0 (0.9)
TG (mmol/l) 1.6 (1.0)
Homocysteine (mol/l) 12 (5)
Fasting glucose (mmol/l) 5.6 (1.6)
Serum creatinine (mmol/l) 0.08 (0.05)
CrCl (ml/min) 79.1 (29.9)
Framingham score (%) 11.1 (9.5)
ECG evidence of ischemia, n (%) 2 (1.5)
Severity and feature of RA:
Radiographic erosion score 24 (35)
Joint space narrowing score 21 (28)
Presence of erosive disease, n (%) 97 (71.3)
History of vasculitis, n (%) 15 (10.9)
Shared epitope, n (%) 103 (75.2)
> 10 mg/day of prednisone, n (%) 9 (6.5)
RAGE polymorphism, n (%) 29 (21.0)
BP, blood pressure; CrCl, creatinine clearance; CRP < C-reactive 
protein; CV, cardiovascular; ECG, electrocardiogram; ESR, 
erythrocyte sedimantation rate; HDL, high-density lipoprotein; LDL, 
low-density lipoprotein; MI, myocardial infarction; PVD, peripheral 
vascular disease; RAGE, receptor for advanced glycation end 
products; RF, rheumatoid factor; TG, triglyceride; TIA, transient 
ischemic attack.
Table 1 (Continued)
Demographic details, cardiovascular risk factors, features of 
rheumatoid arthritis (RA) and its control in the study 
population (n = 138)Available online http://arthritis-research.com/content/11/2/R39
Page 5 of 11
(page number not for citation purposes)
Factors associated with serum levels of S100A9, S100A8 
and S100A12 in patients with RA
We analyzed the cohort of 138 RA patients for associations
between serum levels of S100A9, S100A8, S100A12 and
sRAGE with RA clinical variables, CV risk factors, and with
complications such as vasculitis, radiographic changes, and
CV events. In simple linear regression analysis, we found that
serum levels of S100A9 in RA patients were positively associ-
ated with the presence of the PTPN22 Cys1858Thr genetic
polymorphism, serum levels of S100A12, and serum levels of
S100A8 (Table 2, P < 0.05). Serum levels of S100A9 in MLR
model analysis were positively associated with body mass
index, and with serum levels of S100A8 and S100A12 (Table
2, P < 0.05).
Figure 1
Serum sRAGE, S100A9, S100A8 and S100A12 levels in rheumatoid arthritis (RA) patients and healthy controls Serum sRAGE, S100A9, S100A8 and S100A12 levels in rheumatoid arthritis (RA) patients and healthy controls. Levels of S100A12 (a), S100A9 
(b), S100A8 (c), and soluble receptor for advanced glycation end products (sRAGE) (d) were measured in serum of 138 patients with established 
RA and 44 healthy controls by ELISA. The horizontal line represents the mean value. *** P < 0.001, * P < 0.05.Arthritis Research & Therapy    Vol 11 No 2    Chen et al.
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In simple linear regression analysis, serum levels of S100A8 in
RA patients were positively associated with ACPA, RF, car-
riage of HLA-DRB1*0401, RAGE 82S and of the RA-associ-
ated HLA-DR shared epitope [50], serum levels of S100A9,
S100A12 and radiographic joint space narrowing. Con-
versely, serum levels of S100A8 were negatively associated
with age and serum levels of sRAGE (Table 3, P < 0.05). The
serum levels of S100A8 in MLR analysis were positively asso-
ciated with RF, ACPA and serum levels of S100A9 (Table 3,
P < 0.05).
Table 2
Linear regression analysis of S100A9 in 138 rheumatoid arthritis (RA) patients
Variable  SE t P value 95% Confidence interval
Univariate analysis:
ACPA 0.41 0.21 1.91 0.06 -0.01 to 0.83
Body mass indexa 0.86 0.47 1.84 0.07 -0.07 to 1.78
Diastolic blood pressure 0.02 0.01 1.69 0.09 -0.003 to 0.04
Carriage of PTPN22 Cys1858Thr 0.52 0.24 2.11 0.04 0.03 to 1.00
sRAGEa -0.39 0.20 -1.94 0.06 -0.78 to 0.009
S100A8a 0.20 0.06 3.65 < 0.001 0.09 to 0.31
S100A12a 0.54 0.10 5.46 < 0.001 0.34 to 0.73
Multivariate analysis:
Body mass indexa 0.86 0.41 2.10 0.04 0.05 to 1.67
S100A8a 0.11 0.05 2.05 0.04 0.003 to 0.22
S100A12a 0.46 0.10 4.50 < 0.001 0.26 to 0.67
Variables that were not listed in the simple and multiple linear regression models did not achieve P < 0.1. Adjusted R2 of the multiple linear 
regression model = 0.25.
aLogarithmic (base e) transformation; S100A9 was logarithmically (base e) transformed.
ACPA, anti-citrullinated peptide antibodies; PTPN22, protein tyrosine phosphatase, non-receptor type 22; sRAGE, soluble receptor for advanced 
glycation end products.
Table 3
Linear regression analysis of S100A8 in 138 rheumatoid arthritis (RA) patients
Variable  SE t P value 95% Confidence interval
Univariate analysis:
ACPA 2.23 0.27 8.34 < 0.001 1.70 to 2.76
Age -0.03 0.01 -2.15 0.03 -0.06 to -0.002
RF 2.21 0.26 8.33 < 0.001 1.68 to 2.73
Carriage of HLA-DRB1*0401 1.05 0.32 3.26 0.001 0.41–1.69
Carriage of RAGE 82S 0.83 0.40 2.07 0.04 0.04 to 1.62
Carriage of shared epitope 0.94 0.36 2.63 0.01 0.23 to 1.66
Joint space narrowinga 0.27 0.12 2.31 0.02 0.04 to 0.50
S100A9a 0.48 0.13 3.65 < 0.001 0.22 to 0.75
S100A12a 0.67 0.16 4.23 < 0.001 0.36 to 0.99
sRAGEa -0.77 0.31 -2.51 0.01 -1.37 to -016
Multivariate analysis:
RF 1.45 0.28 5.12 < 0.001 0.89 to 2.01
ACPA 1.22 0.29 4.24 < 0.001 0.65 to 1.79
S100A9a 0.34 0.10 3.42 0.001 0.14 to 0.54
Adjusted R2 of the multiple linear regression model = 0.49.
aLogarithmic (base e) transformation.
ACPA, anti-citrullinated peptide antibodies; HLA, human leukocyte antigen; RF, rheumatoid factor; (s)RAGE, (soluble) receptor for advanced 
glycation end products.Available online http://arthritis-research.com/content/11/2/R39
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In simple linear regression analysis, the serum levels of
S100A12 in RA patients were positively associated with
ACPA, RF, history of diabetes, and serum levels of S100A8
and S100A9 (Table 4, P < 0.05). The serum levels of
S100A12 in RA patients in MLR analysis were positively asso-
ciated with ACPA, a history of diabetes, and serum levels of
S100A9 (Table 4, P < 0.05).
Factors associated with serum levels of sRAGE in 
patients with established RA
Simple linear regression analysis showed that serum sRAGE
levels in RA patients were negatively associated with current
smoking, family history of CV disease, history of vasculitis,
diastolic blood pressure, RF, carriage of RAGE 82Ser, and
serum levels of CRP and S100A8 (Table 5, P < 0.05). MLR
analysis of sRAGE levels confirmed the negative associations
with RAGE 82Ser, history of vasculitis, and with serum levels
of CRP and HDL (Table 5, P < 0.05).
Discussion
We found associations of sRAGE and S100 proteins with
clinical inflammatory factors, complications, and CV risk fac-
tors in established RA patients. S100 A8, A9 and A12 were
all elevated in serum from patients with established RA relative
to healthy controls, and their levels were correlated in RA
patients. By contrast, serum sRAGE levels did not differ in
healthy controls and patients with established RA on treat-
ment. Although a previous study reported reduced levels of
sRAGE in RA compared to healthy control sera [17], it seems
likely that we observed similar levels because of good control
of inflammation in the RA group. In support of this, elevated
serum sRAGE levels were generally associated with a more
favorable vascular risk profile in our RA cohort, and potentially
associated with concomitant reduction in proinflammatory
and/or pro-atherogenic RAGE ligand binding.
Despite the generally negative association of sRAGE with vas-
cular risk factors, the single factor that showed a reverse trend
in multivariate models was serum HDL. Serum HDL levels
were also negatively associated with serum sRAGE among
diabetic subjects with CV disease [51]. In contrast, no associ-
ation with serum HDL and sRAGE was found in patients with
essential hypertension [16]. In spite of its known protective
role, HDL can become proinflammatory [52-54], and inflam-
matory HDL may increase the risk of atherosclerosis in SLE
and RA patients [55,56]. Moreover, HDL function, which is
partly independent of HDL concentration, may be a more crit-
ical determinant of the atheroprotective capacity of HDL [57].
The positive association of S100A9 with S100A8 and
S100A12 suggests that these proteins may be co-regulated
in RA. This is supported by a previous study of S100 proteins
in RA patients [58], and is in keeping with the high S100 gene
expression profiles reported in RA [59]. Despite the positive
associations between of S100A8, A9 and A12 levels, only
S100A12 and S100A8 were associated with RA autoantibod-
Table 4
Linear regression analysis of S100A12 in 138 patients with established rheumatoid arthritis (RA)
Variable  SE t P value 95% Confidence interval
Univariate analysis:
ACPA 0.75 0.16 4.59 < 0.001 0.43 to 1.08
RF 0.62 0.17 3.66 < 0.001 0.29 to 0.96
Carriage of HLA-DRB1*0401 0.32 0.18 1.79 0.08 -0.03 to 0.66
Carriage of shared epitope 0.32 0.19 1.68 0.10 -0.06 to 0.71
History of diabetes 0.52 0.23 2.23 0.03 0.06 to 0.97
S100A9a 0.36 0.07 5.46 < 0.001 0.23 to 0.49
S100A8a 0.19 0.04 4.23 < 0.001 0.10 to 0.28
sRAGEa -0.28 0.16 -1.70 0.09 -0.61 to 0.05
Multivariate analysis:
ACPA 0.63 0.15 4.21 < 0.001 0.33 to 0.93
S100A9a 0.31 0.06 4.87 < 0.001 0.18 to 0.43
History of diabetes 0.43 0.20 2.18 0.03 0.04 to 0.82
Variables that were not listed in the simple linear regression model did not achieve P < 0.1. Adjusted R2 of the multiple linear regression model = 
0.30.
aLogarithmic (base e) transformation. S100A12 was logarithmically (base e) transformed.
ACPA, anti-citrullinated peptide antibodies; HLA, human leukocyte antigen; RF, rheumatoid factor; (s)RAGE, (soluble) receptor for advanced 
glycation end products.Arthritis Research & Therapy    Vol 11 No 2    Chen et al.
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ies including ACPA and RF. Presence of ACPA or RF predicts
a more aggressive RA disease course, including joint erosion
and destruction [60]. Although S100A8/A9 from macro-
phages in RA patients amplified proinflammatory cytokine pro-
duction in one study [11], the properties of serum S100A8/A9
are still debated. S100A8/A9 expression is seen in macro-
phages at the cartilage-pannus junction in RA, and expression
of S100A8 significantly increased in macrophages in RA
patients treated with high dose glucocorticoids compared to
pre-treatment samples [61,62]. Interestingly, glucocorticoids
amplify LPS-induced S100A8 transcription in macrophages in
an interleukin 10-dependent manner. Since we found S100A9
levels were associated with body mass index, it will be of inter-
est to explore the relationship of this protein with endogenous
or exogenous glucocorticoids. Recently, S100A9 or S100A8/
A9 were reported to promote de-differentiation of dendritic
cells and macrophages to myeloid suppressor cells in a tumor-
bearing mouse model, suggesting anti-inflammatory effects of
S100A9 which may reduce antigen-specific priming, for exam-
ple, of cytotoxic T cell responses [63]. In support of an anti-
inflammatory role for S100A9, S100A8 induced TNF in murine
bone marrow cells through TLR4 signaling, and S100A9
negated this activity [64]. We found S100A9 to be associated
with dystrophic calcification [39], which may be of relevance
to atherosclerotic disease, and warrants future investigation in
RA. Thus, the S100A8/A9 complex might have anti-inflamma-
tory properties, or may be related to repair function in dam-
aged or inflamed joints and vessels. It is also plausible that
S100A8/A9 has variable effects depending on the presence
of other disease factors or treatments. Finally, our assay meas-
ured S100A9, whether monomeric or heterocomplexed with
S100A8. The ratio of S100A8:A9 may also play a role, given
that the heterocomplex can have functions distinct from each
protein alone.
In patients with Kawasaki disease, or with chronic hyperglyc-
emia, serum levels of S100A12 were inversely associated with
serum levels of sRAGE [65,66]. Although the inverse correla-
tion between sRAGE and S100A12 did not achieve statistical
significance in the current study, the associations we found
suggest opposing effects on RA severity. S100A12 has
potent inflammatory effects. In chronic inflammatory arthritis,
S100A12 is expressed by infiltrating granulocytes and by syn-
ovial macrophages, is a potent monocyte chemoattractant and
activates mast cells to sequester them in inflammatory lesions
[25,29].
Table 5
Linear regression analysis of sRAGE levels among 138 patients with established rheumatoid arthritis (RA)
Variable  SE t P value 95% Confidence interval
Univariate analysis:
RF -0.23 0.09 -2.56 0.01 -0.41 to -0.05
Current smoker -0.24 0.11 -2.14 0.03 -0.47 to -0.02
Serum creatininea 0.23 0.13 1.77 0.08 -0.03 to 0.49
History of vasculitis -0.29 0.14 -2.07 0.04 -0.57 to -0.01
Family history CVD -0.20 0.10 -2.03 0.04 -0.39 to -0.005
HDLa -0.30 0.17 -1.77 0.08 -0.64 to 0.04
CRPa -0.13 0.05 -2.59 0.01 -0.23 to -0.03
Diastolic blood pressure -0.01 0.004 -2.73 0.007 -0.02 to -0.003
Carriage of RAGE 82S -0.32 0.10 -3.06 0.003 -0.53 to -0.11
S100A8a -0.06 0.03 -2.51 0.01 -0.11 to -0.01
S100A9a -0.08 0.04 -1.94 0.06 -0.15 to 0.002
S100A12a -0.08 0.05 -1.70 0.09 -0.18 to 0.01
Multivariate analysis:
Carriage of RAGE 82S -0.33 0.12 -2.88 0.005 -0.56 to -0.10
HDLa -0.35 0.16 -2.13 0.04 -0.68 to -0.02
CRPa -0.14 0.05 -2.63 0.01 -0.24 to -0.03
History of vasculitis -0.41 0.15 -2.68 0.009 -0.71 to -0.10
Variables that were not listed in the simple linear regression model did not achieve P < 0.1. The selected covariates from simple linear regression 
(P < 0.1) of current smoker, RF, family history of CVD, diastolic blood pressure, creatinine, S100A8 and S100A12 levels were removed from the 
multiple linear regression model because these covariates did not independently correlate with the dependent variable. R2 of the multiple linear 
regression model = 0.24. Adjusted R2 = 0.1
aLogarithmic base e transformation; sRAGE was logarithmically (base e) transformed.
CRP, C-reactive protein; CVD, cardiovascular disease; HDL, high-density lipoprotein; RAGE, receptor for advanced glycation end products; RF, 
rheumatoid factor.Available online http://arthritis-research.com/content/11/2/R39
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Our analysis indicates that sRAGE and S100 proteins are
associated not only with RA inflammation and autoantibody
production, but also with the recruitment of classical vascular
risk factors to end-organ damage. This association with vascu-
lar risk supports previous reports of low sRAGE and high 
S100A8/A9 and S100A12 levels in patients with type 1 and
type 2 diabetes, and essential hypertension [16,66-68]. These
data support evidence from clinical studies of atherosclerosis,
suggesting that the roles of classical risk factors and inflamma-
tion are difficult to separate in RA [69]. As we observed here,
increasing sRAGE levels are associated with a favorable vas-
cular risk profile, potentially associated with concomitant
reduction in proinflammatory and/or pro-atherogenic RAGE
ligand binding [70,71].
Finally, we observed a novel association of low sRAGE levels
with presence of the RAGE 82Ser polymorphism, which is
found more frequently in RA patients [15,19]. It is conceivable
that this, or other linked polymorphisms in the RAGE gene
affect splicing of the C-truncated, endogenously secreted
form of the receptor, or susceptibility to cell surface RAGE
cleavage by matrix metalloproteinases [72], thus altering the
ratio of soluble to membrane RAGE.
Several studies have been published which demonstrate the
role of sRAGE, S100A8/A9 and S100A12 in the long-term
development of vascular disease. These include a negative
association between sRAGE levels and coronary artery dis-
ease in non-diabetic men [41], prediction of unstable plaque
by S100A8/A9 levels in acute coronary syndromes [73], and
of accelerated atherosclerosis by high levels of S100A12 in
hemodialysis patients [74]. However, this is the first time such
an association has been shown with CVD and RA.
Conclusions
sRAGE and S100 proteins were associated with RA inflam-
matory factors and autoantibody production, and with the
recruitment of classical vascular risk factors to end-organ
damage. Consistent with its role as a RAGE decoy molecule,
sRAGE had opposing effects to S100A12 and S100A8 in
RA. Our data suggest that RAGE may mediate a key pathway
coordinating conventional risk factors in the inflammatory RA
setting for co-development of joint and vascular disease. Pro-
spective studies will be of interest to determine the utility of
these proteins as prognostic biomarkers of joint and vascular
damage.
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